By IDSE News Staff
The FDA granted an emergency use authorization (EUA) for another monoclonal antibody (MAB) cocktail to be used for some patients with COVID-19.
This therapy is authorized to treat mild to moderate COVID-19 in patients aged 12 years and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab and etesevimab should be administered together with a single IV infusion as soon as possible after a positive COVID-19 test result and within 10